Ophthalmic Solutions clinical trials
How each study uses Ophthalmic Solutions is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ophthalmic Solutions studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- eye drops
- 3
Studies by the year they started
5 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2014 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. (1) · University of Aarhus (1) · Ace Cells Lab Limited (1) · National University of Malaysia (1) · Chang Gung Memorial Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Ophthalmic Solutions is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Assessment of CataClear, Tear Film Stability, Tear Volume, and Dry Eye Symptoms Using Stem Cells Fortified Eye DropsRecruitingPhase 4Ace Cells Lab LimitedNCT07191847Written as eye drops
- A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsActive, not recruitingPhase 3Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.NCT06209281Written as Lower dose atropine sulfate eye drops
- Umbilical Cord Serum Versus Conventional EyedropsStatus unknownPhase 1/2National University of MalaysiaNCT04217785Written as Optive, Ophthalmic Solution
- Eye Drops Study for Myopia Control in SchoolchildrenStatus unknownNot applicableChang Gung Memorial HospitalNCT03402100Written as eye drops
- Pharmacological Intervention in Diabetic RetinopathyCompletedNot applicableUniversity of AarhusNCT00619034Written as Latanoprost, diclofenac and dorzolamide (eyedrops)
Given beside what is tested · 1 — Ophthalmic Solutions is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Ophthalmic Solutions
Codes
What other systems call Ophthalmic Solutions · ClinicalTrials.gg INT007925
- MeSH (NLM) D009883Ophthalmic SolutionsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D009883 | Ophthalmic Solutions | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.